Down-regulation of CD3zeta is a breast cancer biomarker associated with immune suppression.
This work was done to establish a correlation between serum protein expression profiles and breast cancer. A high-density antibody microarray was used to identify serum protein expression profiles. Proteins up- or down-regulated by 2-fold compared with normal controls were used for hierarchical clustering analysis. ELISA and immunohistochemistry were used for validation of protein array data. The CD3zeta chain was one of the down-regulated molecules identified by the antibody array analysis and confirmed by ELISA and immunohistochemistry. The mean CD3zeta levels in breast cancer and in normal control were 119±23 and 156±35 ng/ml, respectively. The AUC (area under the curve) of CD3zeta was 0.837±0.057. Forty-one out of 65 breast cancer cases (63.08%) showed reduced CD3zeta expression on tumour-infiltrating lymphocytes by immunohistochemistry. This is the first report describing down-regulation of CD3zeta expression on breast cancer for the Chinese population and suggests that an immunosuppressive status plays an important role in breast cancer progression.
Yu
Bin
B
Department of Surgery, The Ninth Peoples Hospital of Shanghai, Shanghai Jiao Tong University, School of Medicine, Shanghai, Peoples Republic of China.
Zhang
Wei
W
D019540:Area Under Curve; D014408:Biomarkers, Tumor / Q000097:blood* / Q000378:metabolism; D001943:Breast Neoplasms / Q000097:blood / Q000276:immunology / Q000378:metabolism*; D017252:CD3 Complex / Q000097:blood* / Q000378:metabolism; D045744:Cell Line, Tumor; D016000:Cluster Analysis; D015536:Down-Regulation; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D007108:Immune Tolerance; D007150:Immunohistochemistry; D040081:Protein Array Analysis
D014408:Biomarkers, Tumor; D017252:CD3 Complex; C121704:CD3 antigen, zeta chain